RA
GSK icon

Riversedge Advisors’s GSK GSK Stock Holding History

Riversedge Advisors’s Portfolio GSK Stock Details GSK Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$234K Buy
4,465
+796
+22% +$42.1K 0.03% 275
2026
Q1 		$202K Buy
+3,669
New +$199K 0.03% 209

Other funds holding GSK

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return
Fisher Asset Management
Fisher Asset Management Camas, Washington $336B AUM 34.66% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
JEST
JTC Employer Solutions Trustee St Helier, Jersey $1.25B AUM 41.83% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Royal Bank of Canada
Royal Bank of Canada Toronto, Ontario, Canada $672B AUM 33.48% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return

Riversedge Advisors's GSK Position: Q2 2026 in Review

Riversedge Advisors increased its GSK (GSK) stake by 22% in Q2 2026, buying an estimated $42.1K and bringing the position to 4,465 shares worth $234K. The position accounts for 0.03% of the portfolio, ranked #275.

Riversedge Advisors first reported a position in GSK in Q1 2026 and has held it in 2 quarters since. 1,037 funds tracked by Wall St. Rank hold GSK as of Q2 2026.

  • Riversedge Advisors held 4,465 shares of GSK worth $234K as of Q2 2026.
  • Riversedge Advisors bought 796 GSK shares in Q2 2026, an estimated $42.1K.
  • GSK made up 0.03% of Riversedge Advisors's portfolio in Q2 2026, its #275 holding.
  • Riversedge Advisors first reported a position in GSK in Q1 2026 and has held it in 2 quarters since.
  • 1,037 funds tracked by Wall St. Rank held GSK as of Q2 2026.

Based on Riversedge Advisors's 13F filing for Q2 2026, filed 16 Jul 2026.